Xencor, Inc.(XNCR)

Description: Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.

---

Keywords: Medicine Biotechnology Cancer Biopharmaceutical Life Sciences Immunology Immune System Antibodies Autoimmune Disease Monoclonal Antibodies Rheumatoid Arthritis Antibody Asthma Glycoproteins Lupus Treatment Of Autoimmune Disease Boehringer Ingelheim Immunoglobulin E Allergic Diseases Severe Asthma Antibody Product Catalent

---

Home Page: www.xencor.com

XNCR Technical Analysis

111 West Lemon Avenue
Monrovia, CA 91016
United States
Phone: 626 305 5900

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)